STAR2026-06-27STAR2026-06-272026-06-27STAR2026-06-272026-06-27UnitOrDivisionOrSubsidiaryDomain1STAR2026-06-27UnitOrDivisionOrSubsidiaryDomain1iso4217:INRxbrli:pure532531STRIDES PHARMA SCIENCE LIMITEDSTARNOTLISTEDINE939A01011NewSale or disposal of unit(s)/division(s)/subsidiarytrue2026-06-2715:50:002026-06-27SubsidiaryPivot Path Private Limited14470000000.0314470000000.0314470000000.033600000000.012026-06-302026-06-30CashThe proposed transaction is with the following investors (Investors): 1.Ascent Growth Trust, a contributory determinate trust established under the Indian Trusts Act, 1882, acting through its investment manager, Ascent Capital Advisors India Private Limited, a leading India-focused private equity investment manager; and 2. Vintage Classic Limited, a company incorporated under the laws of the British Virgin Islands, an Investing Partner of Ascent Capital. Investors do not belong to the Promoter, Promoter Group or Group Companies of Strides Pharma Science Limited Overview of the Transaction The proposed transaction comprises of •Sale of shares by Strides; and •Infusion of primary capital into Pivot Path. Sale of Shares by Strides Strides proposes to divest majority stake in Pivot Path for an aggregate consideration of ~Rs. 1,000 million. Consideration shall be received by Strides, as follows: •Rs. 750 million payable at initial closing; and •Rs. 250 million payable on the first anniversary of closing. Primary Infusion into Pivot Path Ascent Capital propose to infuse Rs. 500 million into Pivot Path to accelerate Pivot Path’s next phase of growth. Resultant Capital Structure of Pivot Path •Strides’ at 19.95%; •Investors at 65.05%; •ESOP Pool at 15% Upon completion of the transaction, Pivot Path shall be reclassified as an Associate Company. Valuation The transaction has been undertaken based on an independent valuation conducted by a SEBI-registered merchant banker, reflecting the strength of Pivot Path's differentiated capabilities, established customer relationships and long-term growth potential.The proposed transaction is with the following investors (Investors): 1. Ascent Growth Trust, a contributory determinate trust established under the Indian Trusts Act, 1882, acting through its investment manager, Ascent Capital Advisors India Private Limited, a leading India-focused private equity investment manager; and 2. Vintage Classic Limited, a company incorporated under the laws of the British Virgin Islands, an Investing Partner of Ascent Capital. Investors do not belong to the Promoter, Promoter Group or Group Companies of Strides Pharma Science Limited.falsefalsetruefalseSale of shares is expected to be completed by June 30, 2026. Primary infusion by Ascent into Pivot Path is expected to be completed by July 31, 2026.